Clinical trial
Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients…
NCT00262301 · Pharming Technologies B.V., Industry · Completed
Key facts
| NCT number | NCT00262301 |
|---|---|
| Title | Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema |
| Official title | A Randomized, Placebo-controlled, Double-blind Phase III Study of the Efficacy and Safety of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema |
| Lead sponsor | Pharming Technologies B.V., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hereditary Angioedema, Angioneurotic Edema, Genetic Disorders |
| Intervention type | Drug |
| Interventions | recombinant human C1 inhibitor, Placebo |
| Enrollment | 75 |
| Start date | Jun 1, 2004 |
| Primary completion | Jul 1, 2009 |
| Completion | Oct 1, 2009 |
| First posted | Dec 6, 2005 |
| Last update posted | Oct 2, 2012 |
| Countries | Netherlands, Romania |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: